Purpose Of Review: The purpose of this manuscript is to review the most recent literature pertinent to the presence of vasculitis in patients with systemic lupus erythematosus (SLE), including previously published landmark articles and studies and to update the different clinical and diagnostic aspects of vasculitic manifestations in patients with this important autoimmune disorder. As a multisystem autoimmune disease, systemic lupus may attack practically any organ system in the human body. Even though vasculitis is not the most common presentation or pathogenic mechanism of disease, it frequently causes significant morbidity and mortality in patients with SLE. The most common manifestation of lupus vasculitis is cutaneous involvement; visceral involvement is less common but causes severe disease; it may occur in different areas including central nervous system, peripheral nervous system, gastrointestinal system, kidneys, lungs and even retina.
Recent Findings: Recent findings regarding the pathogenesis of lupus CNS and peripheral nerve disease, and vascular injury in lupus nephritis are reviewed as well. Vasculitis is an uncommon but serious manifestation of SLE; it may involve different organ systems and present in a wide variety of clinical syndromes, and thus the importance of its recognition and early diagnosis by physicians who deal with this disease, in order to start prompt and aggressive therapy when indicated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11926-020-00937-0 | DOI Listing |
Clin Rheumatol
January 2025
Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Objective: The objective of this study is to present the clinical characteristics of immunoglobulin G4-related diseases (IgG4-RD) patients and describe associated overlap with autoimmune rheumatic diseases (ARDs).
Patients And Methods: This cross-sectional study included 81 patients with IgG4-RD who were recruited from 13 specialized rheumatology departments and centers across the country in collaboration with the Egyptian College of Rheumatology (ECR). Patients underwent a thorough history-taking and clinical examination.
Int Immunopharmacol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan; Immunology Research Center, Chung Shan Medical University, Taichung 402, Taiwan. Electronic address:
Parvovirus B19 (B19V) is a human pathogen from the Parvoviridae family that primarily targets and replicates in erythroid progenitor cells (EPCs). While its symptoms are typically self-limiting in healthy individuals, B19V can cause or exacerbate autoimmune diseases in vulnerable patients. This review integrates the involvement of B19V in the development and worsening of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), hematological disorders (thalassemia, anemia, and thrombocytopenia), vasculitis, antiphospholipid syndrome (APS), dermatological disease (systemic sclerosis, psoriasis), autoimmune thyroid disease, myocarditis, and myasthenia gravis, and autoinflammatory disease of adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFNeurol Neurochir Pol
December 2024
Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Introduction And State Of The Art: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects many organs throughout its course, most frequently the joints, skin and kidneys. Both the central (CNS) and peripheral (PNS) nervous systems are also often affected. T he involvement of the CNS has a negative prognosis in lupus patients.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others.
View Article and Find Full Text PDFDiscov Med
December 2024
Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.
The introduction of immunomodulators as adjuvant therapies in cancer treatment has represented a significant advancement in oncology, improving therapeutic response and patient survival. Emerging targets and molecules could provide new therapeutic opportunities for cancer patients. However, these agents can induce immunological side effects, including vasculitis and connective tissue diseases, which, while uncommon, present significant clinical challenges.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!